Search
Harrow Inc
HROWAdd to Watchlist
41.500USD
-1.180-2.76%
Close 06/25, 16:00（ET）Quotes delayed by 15 min
1.55BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-2.76%
5 Days
-1.05%
1 Month
+25.76%
6 Months
-17.26%
Year to Date
-15.31%
1 Year
+30.87%
Key Figures
42.750Open
43.115High
677.93KVolume
LossP/E TTM
16.65P/E Dynamic
--Dividend TTM
1.82%Turnover Ratio
42.680Prev. Close
41.250Low
22.63MTurnover
LossP/E Static
53.88P/B
0.00%Div Yield TTM
-3.82%ROA
54.85052wk High
0.65Volume Ratio
-17.48MNet Profit
37.27MShares
-0.3849EPS TTM
0.29Beta
-35.14%ROE
25.68052wk Low
4.37%Amplitude
61.18%Gross Margin
1.55BMarket Cap
6.88Reward/Risk
3.49%Risk Rate
TradingKey Stock Score of Harrow Inc
Currency: USD Updated: 2026-06-24Key Insights
Harrow Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 47 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 65.57.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Harrow Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Harrow Inc Highlights
StrengthsRisks
Harrow, Inc. is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the North American market. The Company offers a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 109.15% year-on-year.
Undervalued
The company’s latest PE is -110.89, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 24.67M shares, increasing 1.39% quarter-over-quarter.
Held by Private Capital
Star Investor Private Capital holds 1.60M shares of this stock.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
65.571
Target Price
+53.28%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Harrow Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Harrow Inc Info
Harrow, Inc. is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the North American market. The Company offers a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
Ticker SymbolHROW
CompanyHarrow Inc
CEOMullery (Frank)
Websitehttps://www.harrow.com/
Related Instruments
+1.16%
+1.66%
+1.48%
+3.67%
+4.05%
+1.27%
+0.40%
+0.44%
-1.05%
-1.48%
+1.05%
+0.75%
+1.55%
+1.14%
-0.20%
0.00%
-0.53%
+0.73%
+4.24%
-0.54%Popular Instruments
52024.700
+53.000 (+0.10%)
29455.000
-339.200 (-1.14%)
7366.800
-43.600 (-0.59%)
15751.000
+214.000 (+1.38%)
71132.000
+175.000 (+0.25%)
6265.800
+37.600 (+0.60%)
71.344
+1.585 (+2.27%)
275.150
-17.930 (-6.12%)
195.740
-3.260 (-1.64%)
4026.150
+27.410 (+0.69%)
FAQs
What is the current price of Harrow Inc (HROW)?
The current price of Harrow Inc (HROW) is 42.68.
What is the symbol of Harrow Inc?
The ticker symbol of Harrow Inc is HROW.
What is the 52-week high of Harrow Inc?
The 52-week high of Harrow Inc is 54.85.
What is the 52-week low of Harrow Inc?
The 52-week low of Harrow Inc is 25.68.
What is the market capitalization of Harrow Inc?
The market capitalization of Harrow Inc is 1.59B.
Is Harrow Inc (HROW) currently rated as Buy, Hold, or Sell?
According to analysts, Harrow Inc (HROW) has an overall rating of Buy, with a price target of 65.57.
What is the Earnings Per Share (EPS TTM) of Harrow Inc (HROW)?
The Earnings Per Share (EPS TTM) of Harrow Inc (HROW) is -0.14.
